× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of therapies for COVID19  

RSS

enable push notifications

CT-P59 3.2 part 1 , 2021   NCT04602000 2 weeks ago

regdanvimab (CT-P59 Celltrion) vs. placebo - COVID 19 outpatients NA risk of bias

  • inconclusive results for: Hospitalisation, Oxygen Therapy; hospitalization, high risk patients

risk of bias not assessable

meta-analysis

DEVENT unpublished   NCT04377620 3 weeks ago

ruxolitinib vs. placebo - COVID-19 severe or critically NA risk of bias

  • suggested 53 % decrease in death, all dose

risk of bias not assessable

meta-analysis

INSPIRATION , 2021   NCT04486508 3 weeks ago

anticoagulation, intermediate prophylactic dose vs. anticoagulant, prophylactic dose - COVID-19 severe or critically some concern in risk of bias

  • inconclusive results for: All-cause mortality; Major bleeding; composite of acute venous thromboembolism, arterial thrombosis, treatment with extracorporeal membrane oxygenation, or all-cause mortality

meta-analysis

PATCH Cohort 1 (Amaravadi) , 2021   NCT04329923 4 weeks ago

hydroxychloroquine vs. standard of care - COVID 19 outpatients some concern in risk of bias

  • inconclusive results for: death; developed progressive symptoms; hospitalization

meta-analysis

azithromycin vs. standard of care - COVID-19 mild to moderate some concern in risk of bias

  • inconclusive results for: In-hospital death; seven-level ordinal outcome at 15 days; six-level ordinal outcome at 7 days; use of mechanical ventilation within 15 days; serious adverse event; any adverse event; acute kidney injury within 15 days

meta-analysis

O’Donnell , 2021   NCT04359810 4 weeks ago

convalescent plasma treatment vs. placebo - COVID-19 severe or critically low risk of bias

  • inconclusive results for: 28-day mortality; clinical status at day 28 following randomization, measured using a 7-category ordinal scale; Serious adverse events

meta-analysis

anticoagulant, curative dose vs. control - COVID-19 severe or critically some concern in risk of bias

  • inconclusive results for: Death in hospital; Organ support-free days to day 21a; Major thrombotic events or death; Major bleeding

meta-analysis

Conclusive (statistically conclusive): statistically demonstrated that is statistically significant with a strict control of overall risk of type 1 error, does not take into account the risk of bias; inconclusive: not nominally statistically significant; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error

Follow-us

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits - RSS Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons